학술논문
[Analysis of the state-of-the-art of consulting medical care to patients with glucocorticoid-induced osteoporosis or its risk according to the data of a questionnaire survey (GLUCOST study)].
Document Type
Academic Journal
Author
Baranova IA; Department of Hospital Therapy, Faculty of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia.; Ershova OB; Department of Therapy, Institute of Postgraduate Education, Yaroslavl State Medical Academy, Ministry of Health of Russia, Yaroslavl, Russia.; Anaev EK; Laboratory of Noninvasive Diagnostic Methods, Research Institute of Pulmonary Medicine, Federal Biomedical Agency of Russia, Moscow, Russia.; Anokhina TN; City Polyclinic Two Hundred and Twenty, Moscow Healthcare Department, Moscow, Russia.; Anoshenkova ОN; Tomsk Polyclinic Six, Tomsk, Russia.; Batyn SZ; Laboratory of Intensive Care and Respiratory Failure, Research Institute of Pulmonary Medicine, Federal Biomedical Agency of Russia, Moscow, Russia.; Belyaeva EA; Unit of Rheumatology, Tula Regional Clinical Hospital, Tula, Russia.; Bolshakova TY; Internal Medicine Department One, Faculty of Therapeutics, Prof. V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia, Krasnoyarsk, Russia.; Volkorezov IA; Rheumatology Center, Lipetsk Town Polyclinic Seven, Lipetsk, Russia.; Eliseeva LN; Department of Faculty Therapy, Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia.; Kashnazarova EV; Unit of Pulmonary Diseases, City Clinical Hospital Fifty-Seven, Moscow Healthcare Department, Moscow, Russia.; Kinyaikin MF; Department of Hospital Therapy with Course of Phthisiopulmonology, Pacific State Medical University, Ministry of Health of Russia, Vladivostok, Russia.; Kirpikova MN; Department of Therapy and General Medical Practice, Institute of Postgraduate Education, Ivanovo State Medical Academy, Ministry of Health of Russia, Ivanovo, Russia.; Klyuchnikova EP; Krasnoyarsk Territorial Clinical Hospital, Krasnoyarsk, Russia.; Korolev MA; Research Institute of Clinical and Experimental Lymphology, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia.; Kuneevskaya IV; Allergology Unit, City Clinical Hospital Fifty-Seven, Moscow Healthcare Department, Moscow, Russia.; Masneva LV; Rheumatology Unit, Saint Ioasaf Belgorod Regional Clinical Hospital, Belgorod, Russia.; Muradyants AA; Academician A.I. Nesterov Department of Faculty Therapy, Faculty of Therapeutics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia.; Otteva EN; Rheumatology Center, Prof. S.I. Sergeev Territorial Clinical Hospital One, Ministry of Health of the Khabarovsk Territory, Khabarovsk, Russia.; Petrachkova TN; Irkutsk Regional Clinical Consulting and Diagnostic Center, Irkutsk, Russia.; Peshekhonova LK; Rheumatology Unit, Railway Clinical Hospital at the Voronezh-1 Station, OAO 'RZhD, Voronezh, Russia.; Povzun AS; I.I. Dzhanelidze Saint Petersburg Research Institute of Emergency Care, Saint Petersburg, Russia.; Raskina TA; Department of Internal Medicine Propedeutics, Faculty of Therapeutics, Kemerovo State Medical Academy, Ministry of Health of Russia, Kemerovo, Russia.; Smirnova ML; Vologda Regional Clinical Hospital, Vologda, Russia.; Toroptsova NV; Laboratory of Osteoporosis, V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Sciences, Moscow, Russia.; Khasanova RB; Hospital Therapy Department Two, Acad. E.A. Wagner Perm State Medical Academy, Ministry of Health of Russia, Perm, Russia.; Shamsutdinova NG; Department of Hospital Therapy, Kazan State Medical University, Ministry of Health of Russia, Kazan, Russia.; Shaporova NL; Faculty of Postgraduate Education, Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia, Saint Petersburg, Russia.; Shitova NS; Department of Family Medicine, Northern State Medical University, Ministry of Health of Russia, Saint Petersburg, Russia.; Shkireeva SY; Outpatient Consulting Unit, Saint Petersburg Clinical Rheumatology Hospital Twenty-Five, Saint Petersburg, Russia.; Shostak NA; Academician A.I. Nesterov Department of Faculty Therapy, Faculty of Therapeutics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia.; Lesnyak OM; Department of Family Medicine, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg, Russia.
Source
Publisher: ZAO 'Konsilium Medikum Country of Publication: Russia (Federation) NLM ID: 2984818R Publication Model: Print Cited Medium: Print ISSN: 0040-3660 (Print) Linking ISSN: 00403660 NLM ISO Abbreviation: Ter Arkh Subsets: MEDLINE
Subject
Language
Russian
ISSN
0040-3660
Abstract
Aim: To analyze the state-of-the-art of consulting medical care to Russian patients with glucocorticoid-induced osteoporosis (GCOP) or its risk.
Subjects and Methods: This GLUCOST study was organized and conducted by the Russian Association of Osteoporosis. A total of 1129 patients with chronic inflammatory diseases, who had been taking oral glucocorticosteroids (OGCSs) a long time (3 months or more), were examined. The patients filled out an anonymous questionnaire on their own. Whether the measures taken to diagnose, prevent, and treat GCOP complied with the main points of Russian clinical guidelines was assessed.
Results: 61.8% of the patients knew that the long-term treatment of GCOP might cause osteoporosis. 48.1% of the respondents confirmed the results of bone densitometry; 78.1% of the patients reported that they had been prescribed calcium and vitamin D supplements by their physician, but their regular intake was confirmed by only 43.4%; 25.4% of the patients had sustained one low-energy fracture or more. Treatment for GCOP was prescribed for 50.8% of the patients at high risk for fractures, but was actually received by 40.2%. Therapeutic and diagnostic measures were implemented in men less frequently than in women. When the patient was aware of GCOP, the probability that he/she would take calcium and vitamin D supplements rose 2.7-fold (95% Cl; 2.1 to 3.5; p = 0.001) and that he/she would follow treatment recommendations did 3.5-fold (95% Cl; 2.3 to 5.3; p = 0.001). Bone densitometry increased the prescription rate for antiosteoporotic medication and patient compliance.
Conclusion: According to the data of Russia's large-scale GLUCOST survey, every four patients with chronic inflammatory disease who are on long-term OGCS therapy have one low-energy fracture or more. Due to inadequate counseling, the patients are little aware of their health and do not get the care required to prevent the disease. Less than 50% of patients who have GCOP and a high risk for fractures undergo examination and necessary treatment aimed at preventing fractures.
Subjects and Methods: This GLUCOST study was organized and conducted by the Russian Association of Osteoporosis. A total of 1129 patients with chronic inflammatory diseases, who had been taking oral glucocorticosteroids (OGCSs) a long time (3 months or more), were examined. The patients filled out an anonymous questionnaire on their own. Whether the measures taken to diagnose, prevent, and treat GCOP complied with the main points of Russian clinical guidelines was assessed.
Results: 61.8% of the patients knew that the long-term treatment of GCOP might cause osteoporosis. 48.1% of the respondents confirmed the results of bone densitometry; 78.1% of the patients reported that they had been prescribed calcium and vitamin D supplements by their physician, but their regular intake was confirmed by only 43.4%; 25.4% of the patients had sustained one low-energy fracture or more. Treatment for GCOP was prescribed for 50.8% of the patients at high risk for fractures, but was actually received by 40.2%. Therapeutic and diagnostic measures were implemented in men less frequently than in women. When the patient was aware of GCOP, the probability that he/she would take calcium and vitamin D supplements rose 2.7-fold (95% Cl; 2.1 to 3.5; p = 0.001) and that he/she would follow treatment recommendations did 3.5-fold (95% Cl; 2.3 to 5.3; p = 0.001). Bone densitometry increased the prescription rate for antiosteoporotic medication and patient compliance.
Conclusion: According to the data of Russia's large-scale GLUCOST survey, every four patients with chronic inflammatory disease who are on long-term OGCS therapy have one low-energy fracture or more. Due to inadequate counseling, the patients are little aware of their health and do not get the care required to prevent the disease. Less than 50% of patients who have GCOP and a high risk for fractures undergo examination and necessary treatment aimed at preventing fractures.